サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1606442

帯状疱疹ワクチン市場：製品タイプ別、ワクチンタイプ別、用途別、国別、地域別 - 産業分析、市場用途、市場シェア、2024～2032年予測

Shingles Vaccine Market, By Product Type, By Vaccine Type, By Application, By Country, and By Region - Industry Analysis, Market Application, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 269 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
帯状疱疹ワクチン市場：製品タイプ別、ワクチンタイプ別、用途別、国別、地域別 - 産業分析、市場用途、市場シェア、2024～2032年予測
出版日: 2024年11月04日
発行: AnalystView Market Insights
ページ情報: 英文 269 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

2023年の帯状疱疹ワクチン市場規模は42億5,943万米ドルで、2024年から2032年にかけてCAGR 15.50%で拡大します。

帯状疱疹ワクチン市場 - 市場力学

帯状疱疹に対する意識の高まりと免疫不全疾患の発生率の上昇が市場需要を促進する見込みです。

糖尿病、がん、HIV/AIDSの有病率の増加、免疫抑制剤の使用は、帯状疱疹への感受性を高め、リスクグループにおけるワクチン接種の必要性を押し上げ、市場成長を促進します。ヘルスケア機関による啓発キャンペーンは、帯状疱疹のリスクと帯状疱疹後神経痛（PHN）などの重篤な合併症を強調し、ワクチン摂取を促しています。CDCや各国の保健省は、高齢者の帯状疱疹ワクチン接種を促進する教育イニシアティブを実施しています。WHOによると、世界の60歳以上の人口は2050年までに倍増すると予想されており、対象人口が大幅に拡大します。

ワクチン技術の進歩も市場成長を促進すると予測されています。シングリックス（遺伝子組換え帯状疱疹ワクチン）の開発などの技術革新により、ワクチンの有効性と安全性が向上し、ゾスタバックスのような旧型の弱毒化生ワクチンを上回る採用が進んでいます。最近では、COVID-19の大流行により、感染症予防におけるワクチンの重要性が浮き彫りになり、帯状疱疹を含むその他の重要なワクチンへの関心が高まっています。

帯状疱疹ワクチン市場 - 主要インサイト

弊社リサーチアナリストの分析によると、世界市場は予測期間（2024～2032年）に約15.50%のCAGRで毎年成長すると推定されます。

製品タイプ別では、有害事象に対する有効性から、2023年に市場シングリックスの市場シェアが最大になると予測されています。

ワクチンタイプに基づくと、ウイルス株への幅広い適用により、2023年には組み換えワクチンセグメントがワクチンタイプセグメントをリードしました。

用途別では、主にワクチン接種プログラムの採用が増加していることから、ドラッグデリバリー分野が2023年の主要用途分野となりました。

地域別では、市場上位企業の存在により、北米が2023年の主要収益源でした。

帯状疱疹ワクチン市場 - セグメンテーション分析：

世界の帯状疱疹ワクチン市場は、製品タイプ、ワクチンタイプ、用途、地域に基づいてセグメント化されます。

市場は製品タイプに基づいて3つのカテゴリーに分けられます：シングリックス、Zostavax、SKYZosterです。市場を独占しているのはシングリックスセグメントです。費用対効果の高さから、SKYZoster市場が最も急速に成長すると推定されます。

市場はワクチンの種類によって、組み換えワクチンと弱毒生ワクチンの2つに分類されます。組換えワクチン分野が市場を独占しています。組換えDNA技術の採用により、これらのワクチンは需要が拡大しています。

同市場は、用途に基づき、研究、ドラッグデリバリー、その他の3つのカテゴリーに分類されます。ドラッグデリバリー分野が世界市場を独占しています。ワクチンの長期免疫能とドラッグデリバリーの効率性が、同分野の成長を後押しすると期待されています。

帯状疱疹ワクチン市場 - 地理的洞察

地域的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの各地域に広がっています。北米は帯状疱疹ワクチン市場を独占しており、強力なヘルスケアインフラ、高い認知度、シングリックスのようなワクチンの大幅な普及がその要因となっています。欧州は第2位の市場であり、英国、ドイツ、フランスなどの国々で堅調に普及しています。European Centre for Disease Prevention and Control （ECDC）によるワクチン接種政策の調和に向けた取り組みの活発化が、市場成長を後押しすると期待されています。アジア太平洋は、ヘルスケアへのアクセスの改善、可処分所得の増加、高齢者人口の増加により、急速な成長を遂げています。

帯状疱疹ワクチン市場 - 競合情勢：

帯状疱疹ワクチン市場は、認知度の向上、帯状疱疹の罹患率の上昇、政府によるワクチン接種プログラムの後押しを受け、競争が激しいです。世界市場は、GlaxoSmithKline （GSK）とMerck &Co.GSKのシングリックス・ワクチンは、その高い有効性と高齢者への使用推奨の高まりが主な理由で、大きな市場シェアを占めています。各社はmRNAベースのワクチンに投資しており、SK ChemicalsやGreen Cross Corpなど、革新的なワクチンを導入している企業もあります。

2024年4月、GSKはZOSTER-049試験の結果を発表し、シングリックスが50歳以上の高齢者を効果的に保護することを明らかにしました。

2023年2月には、PfizerとBioNTechがmRNAベースの帯状疱疹ワクチンの臨床試験を開始しました。

目次

第1章 帯状疱疹ワクチン市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 帯状疱疹ワクチンの主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 帯状疱疹ワクチン産業の研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 帯状疱疹ワクチン市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 帯状疱疹ワクチン市場情勢

  • 帯状疱疹ワクチン市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 帯状疱疹ワクチン市場：製品タイプ別

  • 概要
    • 製品タイプ別セグメントシェア分析
    • シングリックス
    • ゾスタバックス
    • スカイゾスター

第8章 帯状疱疹ワクチン市場：ワクチンタイプ別

  • 概要
    • ワクチンタイプ別セグメントシェア分析
    • 組み換えワクチン
    • 生弱毒化ワクチン

第9章 帯状疱疹ワクチン市場：用途別

  • 概要
    • 用途別セグメントシェア分析
    • 調査
    • ドラッグデリバリー
    • その他

第10章 帯状疱疹ワクチン市場：地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析 - 帯状疱疹ワクチン業界

  • 競合ダッシュボード
  • 企業プロファイル
    • GlaxoSmithKline（GSK）
    • Merck &Co., Inc.
    • Pfizer Inc.
    • SK Chemicals
    • Green Cross Corp
    • Geneone Life Science
    • Vaccitech
    • CanSinoBIO
    • Jiangsu Recbio Technology Co., Ltd.
    • MedImmune LLC
    • AbbVie Inc.
    • Sanofi Pasteur
    • VBI Vaccines Inc.
    • Novavax Inc.
    • Bavarian Nordic
    • Others

第12章 アナリストの全方位展望

目次
Product Code: ANV4239

REPORT HIGHLIGHT

Shingles Vaccine Market Application was valued at USD 4,259.43 Million in 2023, expanding at a CAGR of 15.50% from 2024 to 2032.

The shingles vaccine is a medical intervention designed to reduce the risk of developing shingles (herpes zoster), a painful rash caused by the reactivation of the varicella-zoster virus, the same virus responsible for chickenpox. Shingles predominantly affects older adults or individuals with weakened immune systems. The vaccine not only decreases the likelihood of shingles but also reduces the severity and duration of symptoms.

Shingles Vaccine Market- Market Dynamics

Increasing awareness about shingles and rising incidence of immunocompromising disorders is expected to propel market demand

Increasing prevalence of diabetes, cancer, HIV/AIDS, and the use of immunosuppressive drugs increase susceptibility to shingles, boosting the need for vaccination among at-risk groups, thereby fueling market growth. Awareness campaigns by healthcare organizations emphasize the risks of shingles and its severe complications, such as postherpetic neuralgia (PHN), encouraging vaccine uptake. The CDC and national health departments run educational initiatives promoting shingles vaccination among older adults. According to WHO, the global population aged 60 and above is expected to double by 2050, significantly expanding the target demographic.

Advancement in vaccine technology is also projected to enhance market growth. Innovations such as the development of Shingrix (a recombinant zoster vaccine) have improved vaccine efficacy and safety, encouraging adoption over older live-attenuated vaccines like Zostavax. Recently, the COVID-19 pandemic highlighted the importance of vaccines in preventing infectious diseases, spurring interest in other critical vaccines, including shingles.

Shingles Vaccine Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.50% over the forecast period (2024-2032)

Based on Product Type segmentation, the Shingrix segment was predicted to show maximum market share in the year 2023, owing to effectiveness in adverse events.

Based on Vaccine Type segmentation, the recombinant vaccine segment was the leading Vaccine Type segment in 2023, due to wider applications in virus strains.

Based on Application segmentation, the drug delivery segment was the leading Application segment in 2023, mainly due to the rising adoption of vaccination programs.

On the basis of region, North America was the leading revenue generator in 2023, due to the presence of top market players.

Shingles Vaccine Market- Segmentation Analysis:

Global Shingles Vaccine Market is segmented on the basis of Product Type, Vaccine Type, Application, and Region.

The market is divided into three categories based on the Product Type: Shingrix, Zostavax, and SKYZoster. The Shingrix segment dominates the market. The SKYZoster segment is estimated to grow at the fastest rate due to its high cost-effectiveness.

The market is divided into two categories based on Vaccine Type: recombinant vaccine and live attenuated vaccine. The recombinant vaccine segment dominates the market. With the adoption of recombinant DNA technology these vaccines are growing in demand.

The market is divided into three categories based on Application: research, drug delivery, and others. The drug delivery segment dominates the global market. The vaccines' ability to provide long-lasting immunity & efficiency in drug delivery is expected to boost segment growth.

Shingles Vaccine Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America dominates the shingles vaccine market, driven by strong healthcare infrastructure, high awareness, and significant uptake of vaccines like Shingrix. Europe is the second-largest market, with robust adoption in countries like the UK, Germany, and France. Increased efforts by the European Centre for Disease Prevention and Control (ECDC) to harmonize vaccination policies are expected to boost market growth. Asia-Pacific is experiencing rapid growth due to improved healthcare access, rising disposable incomes, and a growing elderly population.

Shingles Vaccine Market- Competitive Landscape:

The shingles vaccine market is highly competitive, driven by increasing awareness, rising incidence of shingles, and government-backed vaccination programs. The global market is dominated by a few key players, with GlaxoSmithKline (GSK) and Merck & Co. leading the field. GSK's Shingrix vaccine has a significant market share, largely due to its high efficacy and the growing recommendation for its use among older adults. Companies are investing in mRNA-based vaccines with some other significant players include SK Chemicals and Green Cross Corp, which are introducing innovative vaccines.

In April 2024, GSK showed results from the ZOSTER-049 trial, which disclosed that Shingrix effectively protected people aged above 50.

In February 2023, Pfizer & BioNTech started trials for mRNA-based shingle vaccines.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SHINGLES VACCINE MARKET KEY PLAYERS

  • GlaxoSmithKline (GSK)
  • Merck & Co., Inc.
  • Pfizer Inc.
  • SK Chemicals
  • Green Cross Corp
  • Geneone Life Science
  • Vaccitech
  • CanSinoBIO
  • Jiangsu Recbio Technology Co., Ltd.
  • MedImmune LLC
  • AbbVie Inc.
  • Sanofi Pasteur
  • VBI Vaccines Inc.
  • Novavax Inc.
  • Bavarian Nordic
  • Others

GLOBAL SHINGLES VACCINE MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019-2032

  • Shingrix
  • Zostavax
  • SKYZoster

GLOBAL SHINGLES VACCINE MARKET, BY VACCINE TYPE- MARKET ANALYSIS, 2019-2032

  • Recombinant vaccine
  • Live attenuated vaccine

GLOBAL SHINGLES VACCINE MARKET, BY APPLICATION- MARKET ANALYSIS, 2019-2032

  • Research
  • Drug delivery
  • Others

GLOBAL SHINGLES VACCINE MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Shingles Vaccine Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Shingles Vaccine Market Snippet by Product Type
    • 2.1.2. Shingles Vaccine Market Snippet by Vaccine Type
    • 2.1.3. Shingles Vaccine Market Snippet by Application
    • 2.1.4. Shingles Vaccine Market Snippet by Country
    • 2.1.5. Shingles Vaccine Market Snippet by Region
  • 2.2. Competitive Insights

3. Shingles Vaccine Key Market Trends

  • 3.1. Shingles Vaccine Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Shingles Vaccine Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Shingles Vaccine Market Opportunities
  • 3.4. Shingles Vaccine Market Future Trends

4. Shingles Vaccine Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Shingles Vaccine Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Shingles Vaccine Market Landscape

  • 6.1. Shingles Vaccine Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Shingles Vaccine Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 7.1.2. Shingrix
    • 7.1.3. Zostavax
    • 7.1.4. SKYZoster

8. Shingles Vaccine Market - By Vaccine Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Vaccine Type, 2024 & 2032 (%)
    • 8.1.2. Recombinant vaccine
    • 8.1.3. Live attenuated vaccine

9. Shingles Vaccine Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 9.1.2. Research
    • 9.1.3. Drug delivery
    • 9.1.4. Others

10. Shingles Vaccine Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Shingles Vaccine Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Shingles Vaccine Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Shingles Vaccine Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Shingles Vaccine Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Shingles Vaccine Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Shingles Vaccine Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. GlaxoSmithKline (GSK)
    • 11.2.2. Merck & Co., Inc.
    • 11.2.3. Pfizer Inc.
    • 11.2.4. SK Chemicals
    • 11.2.5. Green Cross Corp
    • 11.2.6. Geneone Life Science
    • 11.2.7. Vaccitech
    • 11.2.8. CanSinoBIO
    • 11.2.9. Jiangsu Recbio Technology Co., Ltd.
    • 11.2.10. MedImmune LLC
    • 11.2.11. AbbVie Inc.
    • 11.2.12. Sanofi Pasteur
    • 11.2.13. VBI Vaccines Inc.
    • 11.2.14. Novavax Inc.
    • 11.2.15. Bavarian Nordic
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us